Researchers have found a novel, pathogenic entity that is a fundamental link between chronic inflammation and tissue destruction in lungs of patients with COPD. These exosomes from activated ...
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company’s proprietary ...
) has been revised to $137.06 / share. This is an increase of 2,288.89% from the prior estimate of $5.74 dated November 14, 2025. The price target is an average of many targets provided by analysts.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results